• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

tomas.kalincik@unimelb.edu.au

Credentials


Position
Professorial Fellow, Neurological Outcomes
Department of Medicine
Education

Ministry of Health of the Czech Republic
Post Graduate Certificate
University of Melbourne
PhD
University of New South Wales
Bachelors Degree
Charles University in Prague
ORCID

0000-0003-3778-1376

Prof Tomas Kalincik

Professorial Fellow, Neurological Outcomes
Department of Medicine

646 Scholarly works
30 Projects

HIGHLIGHTS

  • 2024

    Research grants (ARC, NHMRC, MRFF)

    New Paradigms in Prevention of Disability in Multiple Sclerosis
  • 2021

    Journal article

    Associations of Disease-Modifying Therapies with COVID-19 Severity in Multiple Sclerosis
    DOI: 10.1212/WNL.0000000000012753
  • 2018

    Research grants (ARC, NHMRC, MRFF)

    Arc Training Centre in Cognitive Computing for Medical Technologies (Arc - Central Operating)
  • 2018

    Research Grant

    Arc Training Centre in Cognitive Computing for Medical Technologies (Arc - Stream 1 & 2)
  • 2015

    Journal article

    Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis
    DOI: 10.1002/ana.24339
  • 2014

    Journal article

    Fingolimod after natalizumab and the risk of short-term relapse
    DOI: 10.1212/WNL.0000000000000283
  • 2013

    Journal article

    Sex as a determinant of relapse incidence and progressive course of multiple sclerosis
    DOI: 10.1093/brain/awt281
Tomas Kalincik

Latest Honours,
Awards and Fellowships


2021
Dame Kate Campbell Professorial Fellowship MDHS, University of Melbourne
2019
Leonard Cox Award ANZAN
2018
NHMRC Fellowship (NHMRCF)
2017
best poster ECTRIMS-ACTRIMS

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Corrigendum to “Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study” [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885] (Multiple Sclerosis and Related Disorders (2026) 106, (S2211034825006236), (10.1016/j.msard.2025.106885))
    DOI: 10.1016/j.msard.2026.107131
  • 2026

    Journal article

    Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder
    DOI: 10.1212/WNL.0000000000214707
  • 2026

    Journal article

    Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.
    DOI: 10.1007/s40263-026-01287-8
  • 2026

    Journal article

    Target trial emulation for causal inference using observational data in neurology.
    DOI: 10.1016/j.neurol.2026.03.001
  • 2026

    Journal article

    Cross-sectional brain volumetric measures and disability outcomes in relapsing–remitting multiple sclerosis
    DOI: 10.1007/s00415-026-13788-z
  • 2026

    Journal article

    Performance of the 2024 McDonald diagnostic criteria for multiple sclerosis
    DOI: 10.1177/13524585261421816
  • 2026

    Journal article

    Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis
    DOI: 10.1093/brain/awaf286
  • 2026

    Journal article

    Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study
    DOI: 10.1016/j.msard.2025.106885

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224